Republic of Korea vs Singapore: Share of adolescent girls vaccinated against human papillomavirus
Republic of Korea
65.0%
in 2024
Singapore
68.0%
in 2024
Republic of Korea rank
38th
Singapore rank
35th
Share of adolescent girls vaccinated against human papillomavirus over time
- Republic of Korea
- Singapore
How they compare
Singapore currently reports 68.0% against 65.0% in Republic of Korea, a difference of 3.0%.
The two have swapped places 1 time across 7 shared years of data; in 2018 it was Republic of Korea ahead.
Republic of Korea ranks 38th and Singapore ranks 35th of 74 countries.
Republic of Korea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Republic of Korea | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 55.5% | 0.0% | 55.5% | Republic of Korea |
| 2020s | 69.4% | 64.4% | 5.0% | Republic of Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of adolescent girls vaccinated against human papillomavirus, Republic of Korea or Singapore?
- Singapore, at 68.0% against 65.0% in Republic of Korea as of 2024.
- What is the difference in share of adolescent girls vaccinated against human papillomavirus between Republic of Korea and Singapore?
- 3.0%, with Singapore ahead.
- How many years of comparable data are there for Republic of Korea and Singapore?
- 7 years are reported by both, from 2018 to 2024.
- How do Republic of Korea and Singapore rank globally for share of adolescent girls vaccinated against human papillomavirus?
- Republic of Korea ranks 38th and Singapore ranks 35th of 74 countries.
- Where does this data come from?
- WHO & UNICEF (2025) – processed by Our World in Data, published as Share of adolescent girls vaccinated against human papillomavirus. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of fifteen-year-old girls who, between the ages of 9 and 14, received their last dose of the human papillomavirus vaccine.